Iroko's acute pain drug Zorvolex wins FDA approval

10/21/2013 | Reuters

Iroko Pharmaceuticals' nonsteroidal anti-inflammatory drug Zorvolex, or diclofenac, was approved by the FDA for treatment of adults with mild to moderate acute pain. Zorvolex was cleared at a 20% lower dose strength than currently available treatments, reducing the risk of strokes, acute renal failures and other serious adverse events.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI